



Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3782747_1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
CK	AA	6,891,036	B2	Inalco S.p.A.	05-10-2005		

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CK	AB	ŽEMLIČKA, J., <i>et al.</i> , "Substrate specificity of ribosomal peptidyltransferase. Effect of modification in the heterocyclic, carbohydrate and amino acid moiety of 2'(3')-O-L-phenyladenosine," <i>Biochemistry</i> , 14(24):5239-5249 (02 December 1975).	
CK	AC	ŽEMLIČKA, J., <i>et al.</i> , "Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. VIII. The preparation of 2'(3')-O-L-phenylalanyluridine, -cytidine, -adenosine, -inosine, -guanosine and 2'-deoxy-3'-O-L-phenylalanyladenosine," <i>Collection Czechoslov., Chem. Commun.</i> , 43(13):3755-3767 (1969).	

Examiner Signature	G. Krizian	Date Considered	12/5/06
-----------------------	------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Specially for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

1

of

8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020.1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
GC	AA	3,798,209	A	Wilkowski, <i>et al.</i>	03-19-1974		
	AB	RE29,835		Witkowski <i>et al.</i>	11-14-1978		
	AC	4,294,766	A	Schmidt <i>et al.</i>	10-13-1981		
	AD	4,522,811	A	Eppstein <i>et al.</i>	06-11-1985		
	AE	4,952,740	A	Juge <i>et al.</i>	08-28-1990		
	AF	4,957,924	A	Beauchamp	09-18-1990		
	AG	5,149,794	A	Yatvin <i>et al.</i>	09-22-1992		
	AH	5,157,027	A	Biller <i>et al.</i>	10-20-1992		
	AI	5,194,654	A	Hostetler <i>et al.</i>	03-16-1993		
	AJ	5,223,263	A	Hostetler <i>et al.</i>	06-29-1993		
	AK	5,256,641	A	Yatvin <i>et al.</i>	10-26-1993		
	AL	5,322,955	A	Matsumoto <i>et al.</i>	06-21-1994		
	AM	5,391,769	A	Matsumoto <i>et al.</i>	02-21-1995		
	AN	5,411,947	A	Hostetler <i>et al.</i>	05-02-1995		
	AO	5,463,092	A	Hostetler <i>et al.</i>	10-31-1995		
	AP	5,543,389	A	Yatvin <i>et al.</i>	08-06-1996		
	AQ	5,543,390	A	Yatvin <i>et al.</i>	08-06-1996		
	AR	5,543,391	A	Yatvin <i>et al.</i>	08-06-1996		
	AS	5,554,728	A	Basava <i>et al.</i>	09-10-1996		
	AT	6,153,594	A	Børretzen <i>et al.</i>	11-28-2000		
	AU	6,248,878	B1	Matulic-Adamic <i>et al.</i>	06-19-2001		
	AV	6,271,212	B1	Chu <i>et al.</i>	08-07-2001		
	AW	6,312,662	B1	Erion <i>et al.</i>	11-06-2001		
	AX	6,566,344	B1	Gosselin <i>et al.</i>	05-20-2003		
	AY	6,569,837	B1	Gosselin <i>et al.</i>	05-27-2003		
	AZ	2002/0019363	A1	Ismaili <i>et al.</i>	02-14-2002		
	AAA	2003/0050229	A1	Sommadossi <i>et al.</i>	03-13-2003		
GC	AAB	2003/0060400	A1	LaColla <i>et al.</i>	03-27-2003		

Examiner
SignatureDate
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

3

of

8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020_1.DOC

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ²
		Office ³	Number	Kind Code ² (if known)				
EC	CA	WO	01/92282	A2&3	Novirio (Idenix); Univ. ... Cagliari	06-12-2001		
	CB	WO	01/96353	A2	Novirio Pharm. (Idenix); C.N.R.S.	21-20-2001		
	CC	WO	02/057287	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CD	WO	02/057425	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CE	WO	02/18404	A2	Hoffman-La Roche AG	03-07-2002		
	CF	WO	02/32414	A2	Schering Corporation	04-25-2002		
	CG	WO	02/32920	A2	Pharmasset	04-25-2002		
	CH	WO	02/48165	A2	Pharmasset	06-20-2002		
	CI	WO	03/024461	A1	Schering Corporation	03-27-2003		
	CJ	WO	04/003138	A2	Merck & Co., Isis Pharmaceutical	01-08-2004		
EC	CK	WO	04/009020	A2	Merck & Co., Isis Pharmaceutical	01-29-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EC	CL	BAGINSKI, S. G. <i>et al.</i> , "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14): 7981-7986 (2000).	
	CM	BATTAGLIA, A.M. <i>et al.</i> , "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <i>Ann. Pharmacother.</i> , 34:487-494 (2000).	
	CN	BEIGELMAN, L.N., <i>et al.</i> , "Functionally complete analogues of nucleosides. The use of D-glucose for the synthesis of 2'-C-methyl-D-ribose derivatives and related nucleosides," <i>Bioorg. Khim.</i> , 12(10):1359-1365 (1986). <i>Abstract in English at p. 1365.</i> <i>Considered English Abstract</i>	Abstract in English at p. 1365
	CO	BEIGELMAN, L.N., <i>et al.</i> , "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose," <i>Carbohydrate Research</i> , 166:219-232 (1987).	
	CP	BENZARIA, S., <i>et al.</i> , "Synthesis of potential prodrugs of β -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001).	
	CQ	BERENGUER, M. <i>et al.</i> , "Hepatitis C virus in the transplant setting", <i>Antivir. Ther.</i> , 3 (Suppl 3):125-136 (1998).	
	CR	BERMAN, E. <i>et al.</i> , "Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells," <i>Blood</i> , 74(4):1281-1286 (1989)	
EC	CS	BHAT <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.); p A75).	

Examiner
Signature

G. Kozlov

Date
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

4

of

8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020_1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
pk	DA	BROWNE, M.J., <i>et al.</i> , "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I trial," <i>J. Infect. Dis.</i> , 167(1):21-29 (1993).	
	DB	BRYANT, M.L., <i>et al.</i> , "Antiviral L-nucleosides specific for hepatitis B virus infection," <i>Antimicrobial Agents and Chemotherapy</i> , 45(1):229-235 (January 2001).	
	DC	CAVELIER, F., <i>et al.</i> , "Studies of selective Boc removal in the presence of silyl ethers," <i>Tetrahedron Letters</i> , 37:5131-5134 (1996).	
	DD	COLACINO, J. M., "Review article: Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)," <i>Antiviral Res.</i> , 29(2-3): 125-39 (1996).	
	DE	CRETTON-SCOTT, E., <i>et al.</i> , "Pharmacokinetics of β -L-2'-deoxycytidine prodrugs in monkeys," <i>Antiviral Res.</i> , 50:A44 (2001).	
	DF	CUI, L., <i>et al.</i> , "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1- β -D-arabinofuranosyl)-5-iodouracil in human liver cells," <i>J. Clin. Invest.</i> , 95:555-563 (1995).	
	DG	DAVIS, G.L., "Current therapy for chronic Hepatitis C," <i>Gastroenterology</i> 118:S104-S114 (2000).	
	DH	De FRANCESCO, R., <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> , 58: 1-16 (2003).	
	DI	De LOMBAERT, S., <i>et al.</i> , "N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors," <i>J. Med. Chem.</i> , 37:498-511 (1994).	
	DJ	DORNSIFE, R.E., <i>et al.</i> , "In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in Human Immunodeficiency Virus-positive humans," <i>Antimicrob. Agents Chemother.</i> , 40(2):514-519 (1996).	
	DK	DYMOCK, B.W., <i>et al.</i> , "Review: Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry & Chemotherapy</i> , 11(2):79-95 (2000).	
	DL	ELDRUP <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.).	
	DM	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy- β -D-psicofuranosyl)purine", <i>Collect. Czech. Chem. Commun.</i> 32:2663-2667 (1967).	
	DN	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C ₁₁ with halo atoms or a mercapto group," <i>Collect. Czech. Chem. Commun.</i> , 31:1535-1543 (1996).	
pk	DO	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate," <i>J. Med. Chem.</i> 26: 1153 (1983);	

Examiner
Signature

G. Karz...

Date
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/735,408
		Filing Date	December 12, 2003
		First Named Inventor	Storer <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	Unassigned
		Attorney Docket Number	06171.105101 IDX 1024
5	of	8	

3474020_1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CK	EA	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential neutral precursors of 9-[β-D-arabinofuranosyl]adenine 5'-monophosphate," <i>J. Med. Chem.</i> 28:1358-1381 (1985).	
	EB	FEAST, A.A.J., <i>et al.</i> , "Studies on the D-glucosaccharinic acids," <i>Acta Chemica Scandinavica</i> 19(5):1127-1134 (1965).	
	EC	FERRARI R., <i>et al.</i> , "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in <i>Escherichia coli</i> ," <i>Journal of Virology</i> , 73(2), 1649-1654 (1999).	
	ED	FISCHL, M.A., <i>et al.</i> , "Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy," <i>Ann. Intern. Med.</i> , 18(10):762-769 (1993).	
	EE	FREED, J.J., <i>et al.</i> , "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," <i>Biochemical Pharmacology</i> . 38:3193-3198 (1989).	
	EF	GUNIC, E., <i>et al.</i> , "Synthesis and cytotoxicity of 4'-C- and 5'-C-substituted Toyocamycins," <i>Bioorg. Med. Chem.</i> , 9:163-170 (2001).	
	EG	HARRY-O'KURU, R.E., J.M. Smith, and M.S. Wolfe, "A short, flexible route toward 2'-C-branched ribonucleosides," <i>J. Org. Chem.</i> 62, 1754-1759 (1997). (Scheme 11).	
	EH	HOSTETLER, K.Y., <i>et al.</i> , "Synthesis and antiretroviral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," <i>J. Biol. Chem.</i> , 265:6112-6117 (April 15, 1990)	
	EI	HOSTETLER, K.Y., <i>et al.</i> , "Greatly enhanced inhibition of Human Immunodeficiency Virus Type I replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine," <i>Antimicrob. Agents Chemother.</i> , 36:2025-2029 (September 1992).	
	EJ	HUNSTON, R.N., <i>et al.</i> , "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine," <i>J. Med. Chem.</i> 27:440-444 (1984).	
	EK	JONES, G. H., and MOFFATT, J. G., "[55] Oxidation of carbohydrates by the sulfoxide-carbodiimide and related methods: Oxidation with dicyclohexylcarbodiimide-DMSO, diisopropylcarbodiimide-DMSO, acetic anhydride-DMSO, and phosphorus pentaoxide-DMSO," <i>Methods in Carbohydrate Chemistry</i> ; Whisler, R. L. and Moffatt, J. L. Eds; Academic Press: New York, 1972; 315-322	
	EL	JONES, G. H., <i>et al.</i> , "4'-substituted nucleosides. 5. Hydroxymethylation of nucleoside 5'-aldehydes," <i>J. Org. Chem.</i> , 44:1309-1317 (1979).	
CK	EM	KEMPE, T., <i>et al.</i> , "Selective 2'-benzoylation at the cis 2',3'-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures," <i>Nucleic Acids Res.</i> , 10(21):6695-6714 (November 11, 1982).	

Examiner Signature		Date Considered	12/5/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

6

of

8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020_1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
GK	FA	KERR, S.G., et al., "N ⁴ -(dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications," <i>J. Pharm. Sci.</i> , 83(4):582-586 (April 1994).	
	FB	KHAMNEI, S., "Neighboring group catalysis in the design of nucleotide prodrugs," <i>J. Med. Chem.</i> , 39:4109-4115 (1996).	
	FC	KILIANI, H., "Ueber Saccharin und Saccharinsäure," <i>Chemische Berichte</i> , 15:2953 (1882). In <i>German. Partial translation in English at pp. 43-44 of the SOWDEN reference.</i>	see SOWDEN
	FD	KOHN, P., et al., "A new method for the synthesis of furanose derivatives of aldohexoses," <i>J. Am. Chem. Soc.</i> , 87(23):5475-5480 (December 5, 1965).	
	FE	KUCERA, L.S., et al., "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," <i>AIDS Res. Hum. Retro Viruses</i> , 6:491-501 (1990).	
	FF	KURTZBERG J., et al., "Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro," <i>Exp. Hematol.</i> , 18(10):1094-1096 (1990).	
	FG	LEONARD, N. J., et al., "5-Amino-5-deoxyribose derivatives. Synthesis and use in the preparation of "reversed" nucleosides" <i>J. Heterocycl. Chem.</i> , 3:485-489 (December 1966).	
	FH	LERZA, R., et al., "In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination," <i>Exp. Hematol.</i> , 25(3):252-255 (1997).	
	FI	LEWIS, W., et al., "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria," <i>J. Clin. Invest.</i> , 89(4):1354-1360 (1992).	
	FJ	LEWIS, L. D., et al., "Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine," <i>Antimicrob. Agents Chemother.</i> , 36(9):2061-2065 (1992).	
	FK	LEWIS, W., et al., "Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts," <i>Proceedings of the National Academy of Sciences, USA</i> , 93(8): 3592-7 (1996).	
	FL	LI, N.-S., et al., "2'-C-branched ribonucleosides. 2. Synthesis of 2'-C- β -trifluoromethyl pyrimidine ribonucleosides," <i>Organic Letters</i> , 3(7):1025-1028 (2001).	
	FM	LOHMANN V., et al., "Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the Hepatitis C virus," <i>Virology</i> , 249, 108-118 (1998).	
GK	FN	LOPEZ-HERRERA, F.J., et al., "A new synthesis of 2-C-methyl-D-ribo-1,4-lactone and the C-/C-13 fragment of methynolide," <i>J. Carbohydrate Chemistry</i> , 13(5):767-775 (1994).	

Examiner
Signature

G. K. K. K.

Date
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

7

of

8

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020_1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
OK	GA	LOPEZ APARICIO, F.J., <i>et al.</i> , "Synthesis of saccharinic acid derivatives," <i>Carbohydrate Res.</i> , 129:99 (1984).	
	GB	LUH, T.-Y., <i>et al.</i> , "A convenient method for the selective esterification of amino-alcohols," <i>Synthetic Communications</i> , 8(5):327-333 (1978).	
	GC	McCORMICK, J., <i>et al.</i> , "Structure and total synthesis of HF-7, a neuroactive glyconucleoside disulfate from the funnel-web spider <i>Hololena curta</i> ," <i>J. Am. Chem. Soc.</i> , 121(24), 5661-5664 (1999).	
	GD	MCKENZIE, R., <i>et al.</i> , "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B", <i>N. Engl. J. Med.</i> , 333(17):1099-1105 (1995).	
	GE	MEDINA, D. J., <i>et al.</i> , "Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-Human Immunodeficiency Virus dideoxynucleosides," <i>Antimicrob. Agents Chemother.</i> , 38(8):1824-8 (1994).	
	GF	MEIER, C., <i>et al.</i> , "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-dideoxythymidine (d4T) - A new pro-nucleic approach," <i>Bioorganic & Med. Chem. Letters</i> 7(2):99-104 (1997).	
	GG	MEYER, R.B., Jr., <i>et al.</i> , "2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid," <i>J. Med. Chem.</i> 22: 811-815 (1979).	
	GH	NEIDLEIN, R., <i>et al.</i> , "Mild preparation of 1-benzyluloxyminoalkylphosphonic dichlorides: Application to the synthesis of cyclic phosphonic diesters and cyclic monoester amides," <i>Heterocycles</i> 35:1185-1203 (1993).	
	GI	NOVÁK, J.J.K. & SORM, F., "Nucleic acid components and their analogues. CXX. 2-C-methyl-D-ribose and its derivatives," <i>Collection Czechoslov. Chem. Commun.</i> , 34:857-866 (1969).	
	GJ	NOVÁK, J.J.K., "Chiroptical properties of 2-methyl-1,4-lactones; revised absolute configuration of 2-deoxy-2-C-methyl-erythro-D-pentono-1,4-lactones," <i>Collection Czechoslov. Chem. Commun.</i> , 39:869-882 (1974).	
	GK	NUTT, R.F., <i>et al.</i> , "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", <i>J. Org. Chem.</i> , 33:1789-1795 (1968).	
	GL	OLSEN, <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76).	
	GM	PAN-ZHOU, X-R., <i>et al.</i> , "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," <i>Antimicrob. Agents Chemother.</i> 44:496-503 (2000).	
	GN	PIANTADOSI, C., <i>et al.</i> , "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity," <i>J. Med. Chem.</i> 34:1408-1414 (1991).	
OK	GO	PIERRA, C., <i>et al.</i> , "Comparative studies of selected potential prodrugs of β -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001), Abstract no. 138.	

Examiner
SignatureDate
Considered

12/5/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

8 of 8

3474020_1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
OK	HA	RICHMAN, D.D., et al., "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-Related Complex," <i>N. Engl. J. Med.</i> , 317(4):192-197 (1987).	
	HB	SCHEIBLER, C., "Ueber das Saccharin und die Saccharinsäure," <i>Chemische Berichte</i> , 13:2212-2217 (1880). In German..	
	HC	SOMMADOSSI J-P, et al., "Comparison of cytotoxicity of the (-)- and (+)- enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells," <i>Biochemical Pharmacology</i> 44(10):1921-1925 (1992).	
	HD	SOMMADOSSI J-P., et al., "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 31:452-454 (1987).	
	HE	SOWDEN, J., "The Saccharinic Acids," <i>Adv. Carbohydrate Chem.</i> , 12:43-46 (1957).	
	HF	STANDRING, D.N., et al., "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," <i>Antiviral Chem. & Chemother.</i> , 12 (Suppl. 1):119-129 (2001).	
	HG	STARRETT, J.E.Jr., et al., "Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agents 9-(2-(phosphonomethoxy)ethyl]adenine (PMEA)," <i>J. Med. Chem.</i> 37: 1857-1864 (1994).	
	HH	TANG, X.-Q., et al., "2'-C-branched ribonucleosides: Synthesis of the phosphoramidite derivatives of 2'-C- β -methylcytidine and their incorporation into oligonucleotides," <i>J. Org. Chem.</i> , 64(3):747-754 (1999).	
	HI	WALTON, E., et al., "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," <i>J. Am. Chem. Soc.</i> , 88(19):4524-4525 (October 5, 1966).	
	HJ	WEINBERG, R.S., et al., "Effect of antiviral drugs and hematopoietic growth factors on in vitro erythropoiesis," <i>Mt. Sinai J. Med.</i> 1998;65(1):5-13.	
	HK	WHISTLER, R.L., and BeMILLER, J.N., "[118] 'a'-D-Glucosaccharino-1,4-lactone," <i>Methods in Carbohydrate Chemistry</i> , 2:484-485 (1963).	
	HL	YARCHOAN, R., et al. "Long-term toxicity / activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex," <i>The Lancet</i> , 336(8714):526-529 (1990).	
	HM	YOSHIDA Y, et al., "Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture," <i>AIDS Res. Hum. Retroviruses</i> , 6(7):929-932 (1990).	
OK	HN	ZON, G., "Cyclophosphamide Analogues," Chapter 4 in <i>Progress in Medicinal Chemistry</i> , Vol. 19, G.P. Ellis and G.B. West, Eds., pp. 205-246 (1982).	

Not available, but also not needed based on description in Sowden article:

Justus Liebigs Annalen Chemie, 213:361 (1883). KILIANI, H.,

OK	BK	WO	0024355	A1	Smith & Nephew Kinetic	05-04-2000	
----	----	----	---------	----	------------------------	------------	--

Examiner Signature	G. Karishma	Date Considered	12/5/06
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.